Recruiting

Phase 1

Personalized TreatmentPersonalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer

Sponsor:

University of Chicago

Code:

NCT06005324

Conditions

HPV-Negative Squamous Cell Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Paclitaxel

Carboplatin

Cetuximab

Standard Dose Radiation

Low Dose Radiation

Study Details

Brief summary:

This clinical trial will assess whether or not blood based biomarker testing can be used to personalize cancer treatment for patients with locally advanced head and neck cancer.

Conditions

HPV-Negative Squamous Cell Carcinoma

Study ID

NCT06005324

Start date

Dec 18, 2023

Status verified date

Jun, 2025

Completion date

Dec, 2026

Anticipated

Primary completion date

Jun, 2026

Anticipated

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Patients must have pathologically confirmed locally advanced, non-metastatic, human papillomavirus (HPV) negative head and neck squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, nasopharynx, larynx, or sinuses.
Stage III or IV disease based on American Joint Committee on Cancer (AJCC) staging 8th edition.
If a primary oropharyngeal squamous cell carcinoma is diagnosed, HPV must be ruled out by immunohistochemistry.
Availability of ≥10 unstained 5 micron slides. Patients who cannot fulfill this requirement will need to undergo a new biopsy prior to enrollment on study.
Patients must be at least 18 years of age.
Measurable disease (either primary site and/or nodal disease) by RECIST 1.1 criteria.
No previous radiation or chemotherapy for a head and neck cancer.
No complete surgical resection for a head and neck cancer within 8 weeks of enrollment (although lymph node biopsy including excision of an individual node with presence of residual nodal disease, or surgical biopsy/excision of the tumor with residual measurable disease is acceptable.) No surgical procedures or core-needle or excisional biopsies will occur after baseline scans are performed and measurable lesions are identified. Fine-needle aspiration can be performed (i.e., to confirm extent of baseline lymph node involvement) following discussion with PI if not performed on a target lesion.
Performance status 0-1
Normal Organ Function

Leukocytes ≥ 3000/mm3
Platelets ≥ 100,000/mm3
Absolute neutrophil count ≥ 1,500
Hemoglobin ≥ 9.0 gm/dL
Aspartate Aminotransferase (AST) ≤ 2.5x upper limit of normal
Alanine aminotransferase (ALT) ≤ 2.5x upper limit of normal
Alkaline phosphatase ≤ 2.5x upper limit of normal
Albumin > 2.9 gm/dL
Total bilirubin ≤ 1.5 mg/dL
Creatinine clearance (CrCl) > 45 mL/min, normal within 2 weeks prior to start of treatment (Of note, the standard Cockcroft and Gault formula must be used to calculate CrCl for enrollment or dosing)
Patients must sign a study-specific informed consent form prior to study entry. Patients should have the ability to understand and the willingness to sign a written informed consent document.
Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug.
Women must not be breastfeeding
Women of childbearing potential must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s) plus 5 months after completing chemoradiation or receiving the last dose of chemoradiation, whichever occurs latest.
Men who are sexually active with women of childbearing potential must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s) plus 5 months after completing chemoradiation or receiving the last dose of chemoradiation, whichever occurs latest.

Exclusion Criteria:

Unequivocal demonstration of distant metastatic disease (M1 disease).
Unidentifiable primary site.
Intercurrent medical illnesses which would impair patient tolerance to therapy or limit survival. This includes but is not limited to ongoing or active infection, immunodeficiency, symptomatic congestive heart failure, pulmonary dysfunction, cardiomyopathy, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance. Patients with clinically stable and/or chronically managed medical illnesses that are not symptomatic and/or are not expected to impact treatment on protocol are still eligible (conditions to be reviewed by the PI to confirm eligibility).
Prior surgical therapy other than incisional/excisional biopsy or organ-sparing procedures such as debulking of airway-compromising tumors. Residual measurable tumor is required for enrollment as discussed above.
Patients receiving other investigational agents.
Diagnosis of immunodeficiency or is receiving systemic steroid therapy in excess of physiologic dose or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
Known history of active tuberculosis (Bacillus Tuberculosis infection).
Hypersensitivity to cetuximab or any other drug used in this protocol.
Prior systemic anti-cancer treatment within the last 8 weeks.
Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer or any tumors that are not likely to influence life expectancy in the subsequent 3 years without active treatment.
Has a history of HIV.
Has known active Hepatitis B or Hepatitis C. If eradicated, patient is eligible.
Has received a live vaccine within 28 days of planned start of study therapy.

Study Design

Enrollment

36 participants

Anticipated

Allocation

Non randomized

Intervention Model

Sequential

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

other: Induction Treatment Arm

All participants will receive 3 cycles (9 weeks) of chemotherapy with paclitaxel, carboplatin, and cetuximab.

experimental: De-Escalation CRT Cohort

After completing induction chemotherapy, participants that have significant disease response by imaging will receive low dose radiation treatment with additional chemotherapy (CRT). Investigator will choose the appropriate chemotherapy backbone to be given during CRT.

active comparator: Standard Treatment Cohort

After completing induction chemotherapy, participants that have limited disease response by imaging will receive standard dose radiation treatment with additional chemotherapy (CRT). Investigator will choose the appropriate chemotherapy backbone to be given during CRT.

Interventions

Paclitaxel

Given as part of induction chemotherapy.

Carboplatin

Given as part of induction chemotherapy.

Cetuximab

Given as part of induction chemotherapy.

Standard Dose Radiation

Radiation given once daily for 5 days for 7 weeks as part of CRT regimen.

Low Dose Radiation

Radiation given once daily for 5 days for 6.5 weeks as part of CRT regimen.

Cisplatin

Given as part of CRT regimen (7 weekly doses). Investigator will choose the appropriate chemotherapy backbone to be given during CRT.

TFHX Regimen

Chemotherapy with paclitaxel, fluorouracil (5FU), and hydroxyurea given in combination with radiation therapy. Investigator will choose the appropriate chemotherapy backbone to be given during CRT.

Primary outcome measure

Percentage of participants that complete study treatment and provide all required research blood draws. [ Time Frame: To be measured at end of treatment period (9 weeks) ]
Determine if ctDNA levels is predicative of disease response [ Time Frame: To be measured at end of treatment period (9 weeks) ]

Central Contacts and Locations

Central contacts

Clinical Trials Intake

1-855-702-8222 cancerclinicaltrials@bsd.uchicago.edu

Locations

University of Chicago Medicine Comprehensive Cancer Center

Recruiting

Chicago, Illinois, United States, 60637

Contacts

Clinical Trials Intake

855-702-8222 cancerclinicaltrials@bsd.uchicago.edu

More Information

Sponsor

University of Chicago

Last update posted

Jun 8, 2025

Last verified

Jun, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by University of Chicago on 2025-06-08.